CTNNB1 and colorectal cancer: Our studies revealed that the quinazoline compounds repress Wnt/β-catenin signaling without altering the level of β-catenin protein in colorectal cancer cells harboring mutations in CTNNB1 or APC, suggesting that they act on the downstream elements of the pathway.